A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

27 Mar 20266 min read0 viewsINTERVENTIONAL Trial

GIST

RECRUITING · INTERVENTIONAL · TREATMENT study · High-Risk Prostate Cancer · Phase 2 · Enrollment 30 · Sponsor: VA Office of Research and Development

Clinical Editorial

Summary

ClinicalTrials.gov published a clinical update in Oncology on 27 Mar 2026. The item focuses on A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss. Open the detail page to review the full original feed content.